 |
Letters of Intent and Full Applications are reviewed by the
Grants Review and Awards Committee which comprises 16 members.
There are twelve external members, representing many of the
leading figures from clinical and academic medicine:
David Lillicrap MD, Kingston, Canada (chairman)
Erik Berntorp MD, Malmö, Sweden
Alison Street, Melbourne, Australia
Craig Kessler, Washington DC, USA
Pier Mannucci MD, Milan, Italy
Johannes Oldenburg MD, Bonn, Germany
Andrea Pritchard RN, MN, Calgary, AB, Canada
Brenda Riske MS, MBA, MPA, Aurora, CO, USA
Alok Srivastava MD, Vellore, India
Marijke van den Berg, Utrecht, Netherlands
Gil White MD, Milwaukee, WI, USA
Akira Yoshioka MD, Nara, Japan
In addition there are four Bayer scientists on the committee.
All members of the Grants Review and Awards Committee will
review the Letters of Intent and determine which candidates
will be invited to submit full applications. Full applications
will be reviewed by at least two members of the committee.
If the proposal falls outside the expertise of the Committee,
it will also be submitted to an ad hoc reviewer who is not
a member of the Grants Review and Awards Committee.
Reviewers will evaluate full applications according to the
criteria outlined in the Awards section
of this website. The reviewers will provide written comments
and preliminary numeric scores according to these criteria.
The Committee will meet to discuss individual proposals including
strengths, weaknesses and scoring. In this meeting, a consensus
score for each grant application will be agreed upon. Proposals
will then be ranked according to these scores in order to
determine funding. In the event of identical scoring, the
Committee will discuss the proposals in question and revise
the scoring in order to clearly define a ranked priority.
Funding will occur on a regional basis.
Three regions are defined as:
- United States and Canada
- Europe (for the purposes of this award, the Europe region
includes Austria, Belgium, Denmark, Finland, France, Germany,
Greece, Italy, Luxembourg, Netherlands, Norway, Portugal,
Spain, Sweden, Switzerland, United Kingdom)
- Japan and all other countries
Awards will be determined on the final priority score as
agreed by the Grants Review and Awards Committee. In the event
that inadequate numbers of acceptable applications are received
from a particular region, additional acceptable proposals
will be funded solely on the basis of priority scores, without
regard to region.
The Committee's decision is final and there is no appeal
mechanism. Applicants who have constructive suggestions about
the review of their applications, or the process in general,
are encouraged to contact us. See Contact.
CONFLICT OF INTEREST
The Program has 'conflict of interest' guidelines that ensure
reviews are conducted in a fair and equitable manner. Reviewers
will not participate in the review or priority scoring of
applications in which they, or institutions with which they
are affiliated, have an interest. Also, to the extent practicable,
reviewers will not participate in the review of proposals
competing for funding with proposals for individuals associated
with their institutions.
CONFIDENTIALITY
The members of the Grants Review and Awards Committee are
bound by the confidentiality rules generally applicable to
such bodies. In certain circumstances, where patentable material
is being discussed, Bayer HealthCare may ask the external
members of the Grants Review and Awards Committee to sign
a more specific confidentiality document.
|
